Synopsis:
In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding of the industry's evolution and the pivotal roles he played at Theravance, Merck, and J&J. The episode delves into the significance of intracellular protein interactions and FogPharma's focus on developing helicon peptides to address this unmet need. Dr. Mammen's emphasis on a moonshot culture at FogPharma, coupled with his strategic approach to commercial success in biotech, makes this episode essential listening for executives in the biotech industry who are looking to stay ahead of future trends and gain insights into the innovative approaches shaping the industry's landscape. His profound knowledge and experience position him as a thought leader, offering invaluable perspectives on the challenges and opportunities in biotech, making this episode a compelling resource for industry executives seeking to implement strategies for commercial success in the biotech sector.
Biography:
Mathai Mammen is a world-renowned innovator in drug discovery, development, and team and company building. He brings significant global R&D and corporate leadership experience to his role as CEO, President and Chairman at FogPharma.
Most recently, Mathai was a member of the executive committee at Johnson & Johnson, where he served as executive vice president of pharmaceuticals, R&D. During his tenure, he spearheaded a significant evolution of Janssen’s R&D, one of the largest R&D organizations in the world. Mathai was a key leader in Johnson & Johnson’s bold foray into COVID vaccines and he helped drive Janssen’s substantial growth to become one of the top pharmaceutical companies globally. Under Mathai’s leadership, Janssen R&D executed 40+ acquisitions and licenses and 350+ strategic partnerships and collaborations. A central pillar of his strategy was data science, which he used to couple recent revolutionary advances in data, compute and algorithmic approaches to every aspect of discovering and developing medicines. Mathai led his team to global approvals of eight new medicines, including Tremfya™, Darzalex Faspro™, Balversa™, Carvykti™, Rybrevant™, Ponvory™, Spravato™ and Tecvayli™, with many additional global approvals for expanded indications of marketed products.
Prior to his role at Johnson & Johnson, Mathai served as senior vice president at Merck, where he was responsible for multiple research areas, including cardiovascular, metabolic and renal diseases, immunology, oncology and immuno-oncology. Before Merck, he led R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides. Under his leadership, Theravance advanced a robust pipeline of multiple development-stage compounds resulting in five approved pharmaceutical products, and separated into two companies: Theravance Biopharma, Inc. and Innoviva, Inc.
In addition to his extensive corporate experience, Mathai currently serves on the board of directors of 10x Genomics, Inc. He has authored more than 150 peer-reviewed publications and patents.
Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.
